Furthermore, a NIH NIAID clinical trial had found that treatment of IFNβ did not improve outcomes for hospitalized patients with COVID-19 and some patients were even associated with more adverse events and worse outcomes. The gene discussed is IFNB1; the disease is COVID-19.